Long-acting delivery and therapies for neovascular age-related macular degeneration.
Lucas W RoweThomas A CiullaPublished in: Expert opinion on biological therapy (2024)
The evolving therapeutic landscape of nAMD is rapidly expanding our toolkit for effective and durable treatment. Recent FDA approvals of faricimab (Vabysmo) and high-dose aflibercept (Eylea HD) for nAMD with potential extension of injection intervals up to four months have been promising developments for patients and providers alike. Further research and innovation, including novel delivery techniques and pharmacologic targets, is necessary to validate the efficacy of developing therapeutics and characterize real-world outcomes, demonstrating promise in expanding treatment durability.
Keyphrases
- age related macular degeneration
- high dose
- end stage renal disease
- chronic kidney disease
- ejection fraction
- small molecule
- type diabetes
- prognostic factors
- machine learning
- big data
- risk assessment
- single cell
- patient reported outcomes
- artificial intelligence
- climate change
- replacement therapy
- weight loss
- patient reported